Incretin research
Cagrilintide vs Retatrutide
Amylin research adjacent to incretin and glucagon literature.
Overview
This comparison separates Cagrilintide and Retatrutide for laboratory reference—not product selection.
Cagrilintide: Novel long-acting lipidated amylin analog functioning as dual amylin and calcitonin receptor agonist for weight management and type 2 diabetes. Phase 3 trials demonstrate 22.7% wei…
Retatrutide: Novel triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors. Phase II trials demonstrated 24.2% weight loss at 48 weeks—the highest recorded for obesity medi…
Differences
- Cagrilintide belongs to amylin analogue research.
- Retatrutide belongs to GLP-1, GIP, and glucagon receptor research.
Mechanism
Cagrilintide: Novel long-acting lipidated amylin analog functioning as dual amylin and calcitonin receptor agonist for weight management and type 2 diabetes. Phase 3 trials d…
Retatrutide: Novel triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors. Phase II trials demonstrated 24.2% weight loss at 48 weeks—the highest recor…
Pharmacology
Cagrilintide: Subcutaneous injection enables optimal bioavailability, targeting dual amylin and calcitonin receptors for satiety and metabolic regulation. insulin sensitivity…
Retatrutide: Pharmacokinetic detail should be read from primary literature.
Research
Cagrilintide: GLP-1 & metabolic: Novel long-acting lipidated amylin analog functioning as dual amylin and calcitonin receptor agonist for weight management and type 2 diabetes. Phase 3…
Retatrutide: GLP-1 & metabolic: Novel triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors. Phase II trials demonstrated 24.2% weight loss at 48 weeks—the high…
Summary
Distinction
- AXIOM does not provide dosing, administration, or protocol guidance.
- Catalogue links appear only where AXIOM lists a research-use product.
- Reference-only compounds remain comparison terms without implying availability.
References
- pubmed.ncbi.nlm.nih.gov/37364590/
- pubmed.ncbi.nlm.nih.gov/40544432/
- pubmed.ncbi.nlm.nih.gov/40544433/
- pubmed.ncbi.nlm.nih.gov/37366315/
- pubmed.ncbi.nlm.nih.gov/40609566/
- pubmed.ncbi.nlm.nih.gov/41090431/
- pubmed.ncbi.nlm.nih.gov/39019866/
- pubmed.ncbi.nlm.nih.gov/37385280/
Questions
Does this page recommend Cagrilintide or Retatrutide?
No. It is an editorial comparison for research context only.
Does AXIOM provide protocol guidance?
No. Protocol and dosing decisions belong with qualified laboratory teams and source literature.
Available from AXIOM
Catalogue
Labelled strengths and batch records where available.